Introduction
Albeit rare overall, emerging ALK-fusion
myofibroblastic/infantile-fibrosarcoma-like spindled-to-ovoid-sarcomas
with tyrosine-kinase RAS::MAPK pathway
fusions1,2, are increasingly identified using next
generation sequencing and other advanced molecular studies for
diagnosis, prognosis, and targeted therapy. Crizotinib treatment ofALK gene mutation tumors, including carcinomas, lymphoma and
neuroblastoma have been reported3. Experience with
targeted therapy in ALK -fusion sarcomas has mostly included
inflammatory myofibroblastic tumor (IMFT)4, yet
treatment of emerging novel ALK -fusions has not previously been
described in detail. Crizotinib, an ALK tyrosine-kinase
inhibitor, is a first-line agent used forALK -mutations3. We demonstrate successful
treatment of a pediatric unique ERC1-ALK fusion sarcoma
interdigitating the right hand that avoided distal forearm amputation by
use of neoadjuvant crizotinib.